1-methylxanthine derived from caffeine as a pharmacodynamic probe of oxypurinol effect

被引:11
作者
Birkett, DJ [1 ]
Miners, JO [1 ]
Valente, L [1 ]
Lillywhite, KJ [1 ]
Day, RO [1 ]
机构
[1] UNIV NEW S WALES,DEPT CLIN PHARMACOL & TOXICOL,SYDNEY,NSW,AUSTRALIA
关键词
1-methylxanthine; caffeine; allopurinol; oxypurinol; xanthine oxidase; pharmacodynamics;
D O I
10.1046/j.1365-2125.1997.53711.x
中图分类号
R9 [药学];
学科分类号
1007 [药学];
摘要
Aims In the present study we have investigated the use of caffeine, administered in the form of instant coffee, as a prodrug for 1MX to validate the use of the 1MU:1MX ratio following caffeine administration as a pharmacodynamic measure of oxypurinol effect on xanthine oxidase. Methods Five healthy volunteers took caffeine 75 mg 8 hourly administered as instant coffee over a 7 day period. They were given allopurinol 600 mg on day 4. Urine was collected in 8 h aliquots from day 1-day 7. The ratio of 1-methyluric acid (1MU) to 1-methylxanthuric (1MX) was determined. Results The relationship between the plasma oxypurinol (the active metabolite of allopurinol) concentration at the midpoint of each caffeine dosage interval and the decrement in the urinary 1MX to 1MU ratio fitted well by a sigmoid E(max) model. Mean (+/-s.d.) values of the oxypurinol EC(50)(3.9 +/- 1.4 mg l(-1)), EC(90)(8.7 +/- 1.8 mg l(-1)) and the exponent, n (3.0 +/- 1.2) were similar to those obtained previously following either the direct administration of 1MX or the use of theophylline as a prodrug for 1MX. Conclusions These data indicate that the use of caffeine as a source of 1MX could provide a simple and ethically acceptable method for monitoring oxypurinol effect in patients taking allopurinol for the treatment of gout.
引用
收藏
页码:197 / 200
页数:4
相关论文
共 8 条
[1]
1-METHYLXANTHINE DERIVED FROM THEOPHYLLINE AS AN INVIVO BIOCHEMICAL PROBE OF ALLOPURINOL EFFECT [J].
BIRKETT, DJ ;
MINERS, JO ;
DAY, RO .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1991, 32 (02) :238-241
[2]
RELATIONSHIP BETWEEN PLASMA OXIPURINOL CONCENTRATIONS AND XANTHINE-OXIDASE ACTIVITY IN VOLUNTEERS DOSED WITH ALLOPURINOL [J].
DAY, RO ;
MINERS, J ;
BIRKETT, DJ ;
GRAHAM, GG ;
WHITEHEAD, A .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1988, 26 (04) :429-434
[3]
Pharmacodynamics of oxypurinol after administration of allopurinol to healthy subjects [J].
Graham, S ;
Day, RO ;
Wong, H ;
McLachlan, AJ ;
Bergendal, L ;
Miners, JO ;
Birkett, DJ .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1996, 41 (04) :299-304
[4]
GRYGIEL JJ, 1979, CLIN PHARMACOL THER, V26, P660
[5]
UNDERSTANDING THE DOSE-EFFECT RELATIONSHIP - CLINICAL-APPLICATION OF PHARMACOKINETIC-PHARMACODYNAMIC MODELS [J].
HOLFORD, NHG ;
SHEINER, LB .
CLINICAL PHARMACOKINETICS, 1981, 6 (06) :429-453
[6]
ASSESSMENT OF CAFFEINE EXPOSURE - CAFFEINE CONTENT OF BEVERAGES , CAFFEINE INTAKE, AND PLASMA-CONCENTRATIONS OF METHYLXANTHINES [J].
LELO, A ;
MINERS, JO ;
ROBSON, R ;
BIRKETT, DJ .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1986, 39 (01) :54-59
[7]
LELO A, 1989, J PHARMACOL EXP THER, V248, P315
[8]
LELO A, 1986, BR J CLIN PHARM, V32, P183